X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA AJANTA PHARMA ALEMBIC PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 26.1 20.7 126.3% View Chart
P/BV x 6.0 8.9 66.6% View Chart
Dividend Yield % 0.8 0.7 117.8%  

Financials

 ALEMBIC PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
AJANTA PHARMA
Mar-16
ALEMBIC PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs7921,720 46.0%   
Low Rs4431,103 40.2%   
Sales per share (Unadj.) Rs167.0194.6 85.8%  
Earnings per share (Unadj.) Rs38.245.2 84.4%  
Cash flow per share (Unadj.) Rs42.050.3 83.5%  
Dividends per share (Unadj.) Rs4.008.00 50.0%  
Dividend yield (eoy) %0.60.6 114.3%  
Book value per share (Unadj.) Rs84.9132.0 64.3%  
Shares outstanding (eoy) m188.5288.77 212.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.77.3 51.0%   
Avg P/E ratio x16.231.2 51.8%  
P/CF ratio (eoy) x14.728.1 52.4%  
Price / Book Value ratio x7.310.7 68.0%  
Dividend payout %10.517.7 59.2%   
Avg Mkt Cap Rs m116,383125,299 92.9%   
No. of employees `000NANA-   
Total wages/salary Rs m4,2142,570 164.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m31,48717,275 182.3%  
Other income Rs m55166 33.1%   
Total revenues Rs m31,54217,442 180.8%   
Gross profit Rs m10,0605,807 173.2%  
Depreciation Rs m722451 160.3%   
Interest Rs m3749 75.3%   
Profit before tax Rs m9,3565,474 170.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1601,460 148.0%   
Profit after tax Rs m7,1944,014 179.2%  
Gross profit margin %31.933.6 95.0%  
Effective tax rate %23.126.7 86.6%   
Net profit margin %22.823.2 98.3%  
BALANCE SHEET DATA
Current assets Rs m15,0667,639 197.2%   
Current liabilities Rs m7,6742,715 282.7%   
Net working cap to sales %23.528.5 82.4%  
Current ratio x2.02.8 69.8%  
Inventory Days Days6743 154.9%  
Debtors Days Days4179 51.6%  
Net fixed assets Rs m8,2376,914 119.1%   
Share capital Rs m377177 213.1%   
"Free" reserves Rs m15,41611,442 134.7%   
Net worth Rs m16,00511,721 136.6%   
Long term debt Rs m0149 0.0%   
Total assets Rs m24,59414,814 166.0%  
Interest coverage x255.2112.9 226.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.31.2 109.8%   
Return on assets %29.427.4 107.2%  
Return on equity %44.934.2 131.2%  
Return on capital %58.746.5 126.1%  
Exports to sales %55.755.1 101.1%   
Imports to sales %10.46.0 173.6%   
Exports (fob) Rs m17,5519,527 184.2%   
Imports (cif) Rs m3,2831,038 316.4%   
Fx inflow Rs m17,81110,422 170.9%   
Fx outflow Rs m5,3181,678 316.9%   
Net fx Rs m12,4938,744 142.9%   
CASH FLOW
From Operations Rs m9,3043,264 285.1%  
From Investments Rs m-3,105-2,093 148.3%  
From Financial Activity Rs m-1,959-1,186 165.2%  
Net Cashflow Rs m4,240-15 -28,648.6%  

Share Holding

Indian Promoters % 74.1 73.8 100.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 1.6 187.1%  
FIIs % 9.1 7.6 119.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 17.0 81.8%  
Shareholders   49,328 20,968 235.3%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  CIPLA  TORRENT PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 23, 2017 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - SUVEN LIFE COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS